Riskpilot← Back to searchSign inGet full accessEmrad medkonsult AB
ABActiveOrg 5590343520Södra Vägen 14General medical practice activities · NACE 8621Est. 20152 employees
Revenue 2025
SEK 0
EBITDA margin
—
-145% vs 2024
Equity ratio
98.1%
Financial strength
Net profit 2025
SEK -14K
-156% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -14K | -145% |
| Net profit | SEK -14K | -156% |
| Total assets | SEK 216K | -10% |
| Equity | SEK 212K | -6% |
| Employees | 2 | — |
Legal name
Emrad medkonsult AB
Org number
5590343520
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
10 november 2015
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva medicinsk konsultverksamhet, utbildning (inklusive framställande av utbildningsmaterial) och verksamhetsutveckling samt därmed förenlig verksamhet. Bolaget ska dessutom bedriva uthyrning av hälso- och sjukvårdspersonal.
Address
Södra Vägen 14
Email
info@emrad.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 165 | 155 | 60 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −31 | 128 | 129 | 31 | −14 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −31 | 128 | 129 | 31 | −14 |
| Net financials | — | — | — | — | — |
| Profit before tax | −31 | 128 | 129 | 31 | −14 |
| Tax | −0 | −20 | −27 | −6 | −0 |
| Net profit | −31 | 108 | 102 | 25 | −14 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 189 | 337 | 340 | 240 | 216 |
| Equity | 191 | 299 | 301 | 226 | 212 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 | 38 | 39 | 14 | 4 |
| Total debt | 3 | 38 | 39 | 14 | 4 |
EBITDA margin
-1400000.0%
This company
15.8%
Market median
-8860859% vs market
20212025
Equity ratio
98.1%
This company
38.2%
Market median
+157% vs market
20212025
Return on equity
-6.6%
This company
18.4%
Market median
-136% vs market
20212025
Net profit margin
-1400000.0%
This company
8.1%
Market median
-17284051% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Emrad medkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jonas Gustav Lindström | Chairman | 0 companies |
| Frida Margareta Meyer | Board of Directors | 0 companies |
| Linnea Margareta Meyer Ridbäck | Deputy Board Member | 0 companies |